GlassScriptPhysician profile
Robert M Goldberg
NPI 1215054168
$1,778.27
in general payments reported to CMS, 2019-2025
33 companies · $153 in 2025
The $153 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $495 · 2020: $163 · 2021: $90.45 · 2022: $418 · 2023: $285 · 2024: $174 · 2025: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $514 · Education: $98.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $513.57 |
| Education | $98.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $211.36 | 2019-2023 | Opdivo |
| Allergan, INC. | $174.05 | 2019-2020 | |
| Incyte Corporation | $156.11 | 2019-2025 | Zynyz, Monjuvi |
| Pharmacyclics LLC, An Abbvie Company | $139.52 | 2022-2023 | Imbruvica, Epkinly |
| Bayer Healthcare Pharmaceuticals INC. | $111.96 | 2019-2025 | |
| Amarin Pharma, INC. | $108.99 | 2019 | |
| Asd Specialty Healthcare, LLC | $100.40 | 2019 | |
| Genzyme Corporation | $74.05 | 2020-2025 | |
| Amgen INC. | $68.76 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $60.81 | 2019-2023 | Keytruda, Lynparza |
| Janssen Biotech, INC. | $55.05 | 2021-2025 | Erleada, Balversa, Akeega |
| Taiho Oncology, INC. | $49.37 | 2022-2023 | |
| Coherus Oncology, INC. | $45.38 | 2022-2024 | |
| Daiichi Sankyo INC. | $44.53 | 2022-2024 | Enhertu |
| Celgene Corporation | $39.92 | 2022-2023 | Opdualag |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $39.49 | 2021-2024 | Libtayo |
| Pharmaessentia USA Corporation | $36.07 | 2025 | Besremi |
| Sobi, INC | $29.64 | 2024-2025 | |
| Abbvie INC. | $28.29 | 2024 | |
| Servier Pharmaceuticals LLC | $21.45 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $16.77 | 2022 | |
| Adc Therapeutics America, INC. | $15.46 | 2023 | |
| Blueprint Medicines Corporation | $15.15 | 2025 | Ayvakit |
| Tempus Ai, INC | $15.13 | 2024 | |
| Azurity Pharmaceuticals, INC. | $14.56 | 2025 | Danziten |
| Morphosys, US INC. | $14.22 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $14.13 | 2022 | |
| Foundation Medicine, INC. | $14.02 | 2019 | |
| Astellas Pharma US INC | $13.57 | 2020 | |
| Eisai INC. | $13.39 | 2023 | |
| Kite Pharma, INC. | $12.90 | 2021 | |
| Pfizer INC. | $12.22 | 2021 | |
| Epizyme, INC. | $11.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Goldberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.